Floatz logo

FDOPA

Autonomic Nervous System Disorder

Daniel ClaassenSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Autonomic Nervous System Disorder cohort.

Asset / SponsorPhaseRating
Entacapone
Daniel Claassen
Phase 1/2CCC
Droxidopa
Vanderbilt University Medical Center
Phase 1/2CCC
Carbidopa
Daniel Claassen
Phase 1/2CCC
Midodrine
Vanderbilt University Medical Center
Phase 1CCC
Fezolinetant
Shehzad Basaria, M.D.
Phase 2CCC

View all 12 →

Same molecule, other indications

FDOPA is also rated in:

congenital isolated hyperinsulinismActive
BB
Indicative · Phase 3
66 / 100
View asset →
brain gliomaDormant
B
Indicative · Phase 3
63 / 100
View asset →
Lewy body dementiaActive
B
Indicative · Phase 3
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →